摘要
恶性黑色素瘤是一种侵袭性极强的肿瘤,在早期可行外科手术切除治疗。晚期黑色素瘤细胞的侵袭能力和增殖能力不断增强,传统治疗方法如放疗、化疗和免疫治疗等效果有限,患者预后差。由于恶性黑色素瘤发病存在多条分子通路的突变,因而靶向治疗成为晚期恶性黑色素瘤患者较为可行的治疗方法,多数患者可以从靶向治疗中获益。然而靶向治疗耐药性一直是黑色素瘤治疗急需解决的问题,耐药性的出现严重影响了疗效,因此对于耐药机制的探索和研究十分必要。
Malignant melanoma is an extremely aggressive tumor that can be surgically treated in its early stage.In advanced stages,the invasive and proliferative capabilities of melanoma cells continue to increase,and traditional treatment methods such as radiotherapy,chemotherapy,and immunotherapy have limited efficacy,resulting in poor patient prognosis.Due to the presence of mutations in multiple molecular pathways in malignant melanoma,targeted therapy is now regarded as a more viable treatment option for patients with advanced malignant melanoma,with most patients benefiting from it.However,the development of drug resistance to targeted therapy has always been a serious challenge,as the emergence of resistance limits the efficacy.Therefore,it is necessary to explore the mechanism and drug resistance of targeted therapy of malignant melanoma.
作者
刘一帆
罗星
宋天慈
杨志惠
LIU Yifan;LUO Xing;SONG Tianci;YANG Zhihui(School of Basic Medical Sciences,Southwest Medical University,Luzhou Sichuan 646000;Key Laboratory for Precision Pathological Diagnosis of Major Diseases,Luzhou Sichuan 646000;Affiliated Hospital of Southwest Medical University,Luzhou Sichuan 646000;School of Clinical Medicine,Qilu Medical University,Zibo Shandong 255300,China)
出处
《昆明医科大学学报》
2025年第2期158-163,共6页
Journal of Kunming Medical University
基金
国家自然科学基金(82273395)。
关键词
恶性黑色素瘤
靶向治疗
耐药机制
Malignant melanoma
Targeted therapy
Drug resistance mechanisms
